Day two of the 2023 #Cantor Global Healthcare Conference commenced with thought-provoking presentations from notable companies, including:

• PAVmed Inc. / Lucid Diagnostics (#PAVM) (#LUCD) | Moderated by Ross Osborn, CFA – Dr. Lishan Aklog, MD (Chairman & CEO) discussed trends to increasing testing volumes coupled with a clear path to improving pricing.

• Zai Lab (#ZLAB) | Moderated by Louise Chen – Josh Smiley (President & COO) discussed the latest China regulatory landscape, the importance of NRDL in China, and how ZLAB differentiates itself from other China-based biotech. Management focused on ZLAB’s five commercial products, as well as the potential and new launches including Vyvgart (efgartigimod), TTFields, and SUL-DUR. Josh also talked about the current status and future development strategies for ZLAB’s other assets, KarXT, Krazati, and Margenza.

• Equillium, Inc. (#EQ) and Eledon Pharmaceuticals, Inc. (#ELDN) Panel Presentation | Moderated by Prakhar Agrawal and Pete Stavropoulos – Equillium Management provided an overview of EQ101 mechanism and their expectations for the upcoming readout in alopecia areata.

• Aptose Biosciences, Inc. (#APTO), Curis (#CRIS), SELLAS Life Sciences Group, Inc. (#SLS), and Vincerx Pharma, Inc. (#VINC) | Moderated by Li Watsek – William Rice (APTO CEO), Diantha Duvall (CRIS CFO), Dr. Angelos M. Stergiou, MD,ScD hc (SLS President & CEO), and Ahmed Hamdy, MD (VINC CEO), discussed their strategies for attacking relapsed/refractory Acute Myeloid Leukemia, and how new technologies/targets can bring benefit to some of the patient subgroups with highest unmet medical need.

#CantorFitzgerald #CantorHealthcare #CantorGlobalHealthcare2023